NCT01327612 2021-02-21Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)AmgenPhase 2 Completed12 enrolled 21 charts
NCT00563680 2016-10-27QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell TumorsNantCell, Inc.Phase 2 Completed38 enrolled
NCT00562380 2013-07-18AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1 Completed64 enrolled